Welcome to Merz Therapeutics North America

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is a global healthcare leader dedicated to improving the lives of patients around the world. With our relentless research, development, and culture of innovation, we strive to serve unmet patient needs and realize better outcomes.

Our Merz Therapeutics North America business is comprised of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C.

News

Xeomin® (IncobotulinumtoxinA) Celebrates 10 Years of Meeting the Needs of Patients Suffering from Movement Disorders

Merz Therapeutics is commemorating today the 10th anniversary of the first therapeutic approval of XEOMIN by the U.S. Food and Drug Administration.

Read More

MERZ FORMS FULLY FOCUSED GLOBAL MEDICAL AESTHETICS BUSINESS: MERZ AESTHETICS

Merz, a global leader in the field of aesthetics and neurotoxins, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care.

Read More

FDA Approves Broadened Indication for XEOMIN® (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients

Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN®(incobotulinumtoxinA), broadening its indication to be a first-line treatment of blepharospasm (involuntary blinking) in adult patients.

Read More